You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

REZAFUNGIN ACETATE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for rezafungin acetate and what is the scope of patent protection?

Rezafungin acetate is the generic ingredient in one branded drug marketed by Mundipharma and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rezafungin acetate has ninety-two patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for REZAFUNGIN ACETATE
International Patents:92
US Patents:7
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 14
Clinical Trials: 1
Patent Applications: 3
DailyMed Link:REZAFUNGIN ACETATE at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REZAFUNGIN ACETATE
Generic Entry Date for REZAFUNGIN ACETATE*:
Constraining patent/regulatory exclusivity:
GENERATING ANTIBIOTIC INCENTIVES NOW
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for REZAFUNGIN ACETATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mundipharma Research LimitedPhase 1

See all REZAFUNGIN ACETATE clinical trials

Pharmacology for REZAFUNGIN ACETATE

US Patents and Regulatory Information for REZAFUNGIN ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mundipharma REZZAYO rezafungin acetate POWDER;INTRAVENOUS 217417-001 Mar 22, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Mundipharma REZZAYO rezafungin acetate POWDER;INTRAVENOUS 217417-001 Mar 22, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mundipharma REZZAYO rezafungin acetate POWDER;INTRAVENOUS 217417-001 Mar 22, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Mundipharma REZZAYO rezafungin acetate POWDER;INTRAVENOUS 217417-001 Mar 22, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mundipharma REZZAYO rezafungin acetate POWDER;INTRAVENOUS 217417-001 Mar 22, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for REZAFUNGIN ACETATE

Country Patent Number Title Estimated Expiration
Japan 6111447 ⤷  Sign Up
Poland 2680873 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2017161016 ⤷  Sign Up
Israel 274829 תכשיר פרמצבטי המכיל תרכובת אצ'ינוקנדין ושימוש בתכשיר מיובש בהקפאה המכיל תרכובת אצ'ינוקנדין בהכנת תמיסה מימית לטיפול בזיהום פטריתי (A pharmaceutical composition comprising an echinocandin compound and use of a lyophilized composition comprising an echinocandin compound in the preparation of an aqueous solution for treating a fungal infection) ⤷  Sign Up
Slovenia 3677252 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.